News

Filter

Current filters:

Maxipime

1 to 9 of 37 results

Tysabri sales improve Elan's 2nd-qtr loss 49%

04-08-2008

Irish biotechnology firm Elan's second-quarter 2008 net loss narrowed 49% year-on-year to $71.5 million,…

Biogen IdecCefepime Hydrochloride for InjectionMaxipimeNatalizumabTysabri

Elan's 1st-qtr 2008 loss narrows 8% on Tysabri

05-05-2008

Elan's first-quarter 2008 loss narrowed year-on-year thanks to higher income from multiple sclerosis…

Amino AcidsBiogen IdecCefepime Hydrochloride for InjectionInjectionMaxipimeNatalizumabPhysostigmine SalicylateTysabri

Elan's 2007 loss up 51% on charges

25-02-2008

Dublin, Ireland-based Elan Corp said that its net loss for the fourth quarter of 2007, which at $83.5…

Biogen IdecCefepime Hydrochloride for InjectionMaxipimeNatalizumabTysabri

FDA issues early warnings on Elan's Maxipime

26-11-2007

The US Food and Drug Administration has issued an early communication about an article in the May issue…

Cefepime Hydrochloride for InjectionMaxipime

Elan sees 3rd-qtr loss narrow, sales rise 43%

12-11-2007

Dublin, Ireland-based Elan Corp says that the continuing momentum of its multiple sclerosis drug Tysabri…

Amino AcidsBiogen IdecCefepime Hydrochloride for InjectionInjectionMaxipimeNatalizumabPhysostigmine SalicylatePrialtTysabriZiconotide

Elan's 2nd-qtr 2007 loss deepens 56%

06-08-2007

Irish drugmaker Elan says that its net loss for the three months ended June 30, 2007, amounted to $141.1…

Amino AcidsCefepime Hydrochloride for InjectionInjectionMaxipimeNatalizumabPhysostigmine SalicylatePrialtTysabriZiconotide

1 to 9 of 37 results

COMPANY SPOTLIGHT

Menarini

Back to top